CN115667243B - 作为nrf2活化剂的四氢异喹啉化合物 - Google Patents

作为nrf2活化剂的四氢异喹啉化合物 Download PDF

Info

Publication number
CN115667243B
CN115667243B CN202180031435.0A CN202180031435A CN115667243B CN 115667243 B CN115667243 B CN 115667243B CN 202180031435 A CN202180031435 A CN 202180031435A CN 115667243 B CN115667243 B CN 115667243B
Authority
CN
China
Prior art keywords
methyl
disease
fluoro
chloro
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180031435.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115667243A (zh
Inventor
凯茜·路易丝·卢卡斯
尼古拉斯·查尔斯·雷
艾琳·玛丽·苏华德
乔治·海德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C4X Discovery Ltd
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of CN115667243A publication Critical patent/CN115667243A/zh
Application granted granted Critical
Publication of CN115667243B publication Critical patent/CN115667243B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180031435.0A 2020-04-22 2021-04-22 作为nrf2活化剂的四氢异喹啉化合物 Active CN115667243B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005863.2 2020-04-22
GBGB2005863.2A GB202005863D0 (en) 2020-04-22 2020-04-22 Therapeutic compounds
PCT/GB2021/050973 WO2021214470A1 (en) 2020-04-22 2021-04-22 Tetrahydroisoquinoline compounds as nrf2 activators

Publications (2)

Publication Number Publication Date
CN115667243A CN115667243A (zh) 2023-01-31
CN115667243B true CN115667243B (zh) 2025-01-07

Family

ID=70860156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031435.0A Active CN115667243B (zh) 2020-04-22 2021-04-22 作为nrf2活化剂的四氢异喹啉化合物

Country Status (16)

Country Link
US (1) US20230167084A1 (cg-RX-API-DMAC7.html)
EP (1) EP4139294B1 (cg-RX-API-DMAC7.html)
JP (1) JP7679400B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230004720A (cg-RX-API-DMAC7.html)
CN (1) CN115667243B (cg-RX-API-DMAC7.html)
AR (1) AR121912A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021259366A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174361A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032247T3 (cg-RX-API-DMAC7.html)
GB (1) GB202005863D0 (cg-RX-API-DMAC7.html)
IL (1) IL297434A (cg-RX-API-DMAC7.html)
MX (1) MX2022013398A (cg-RX-API-DMAC7.html)
PH (1) PH12022552775A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021214470A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211465B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY207469A (en) * 2018-10-22 2025-02-27 C4X Discovery Ltd Therapeutic compounds
CR20240325A (es) * 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2
WO2025237912A1 (en) 2024-05-13 2025-11-20 Astrazeneca Ab Keap1 inhibitors for use in the treatment of bronchiectasis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084300A1 (en) * 2018-10-22 2020-04-30 C4X Discovery Limited Therapeutic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20140256767A1 (en) * 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
KR20180017038A (ko) * 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
JP2020097526A (ja) 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084300A1 (en) * 2018-10-22 2020-04-30 C4X Discovery Limited Therapeutic compounds

Also Published As

Publication number Publication date
AR121912A1 (es) 2022-07-20
JP2023524206A (ja) 2023-06-09
EP4139294B1 (en) 2025-04-09
EP4139294A1 (en) 2023-03-01
JP7679400B2 (ja) 2025-05-19
CN115667243A (zh) 2023-01-31
KR20230004720A (ko) 2023-01-06
CA3174361A1 (en) 2021-10-28
MX2022013398A (es) 2022-12-13
US20230167084A1 (en) 2023-06-01
ZA202211465B (en) 2025-06-25
AU2021259366A1 (en) 2022-11-10
GB202005863D0 (en) 2020-06-03
WO2021214470A1 (en) 2021-10-28
PH12022552775A1 (en) 2024-03-25
BR112022021244A2 (pt) 2022-12-06
IL297434A (en) 2022-12-01
ES3032247T3 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
JP7719250B2 (ja) 治療用化合物
CN115667242B (zh) 作为nrf2活化剂的四氢异喹啉化合物
JP7679400B2 (ja) Nrf2活性化剤としてのテトラヒドロイソキノリン化合物
CN116462687A (zh) Wee1抑制剂及其制备和用途
HK40088672A (en) Isoquiniline nrf2 agonists
HK40088672B (en) Isoquiniline nrf2 agonists
EA049312B1 (ru) ТЕТРАГИДРОИЗОХИНОЛИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ АКТИВАТОРОВ Nrf2
HK40101413A (en) Therapeutic compounds
EA047580B1 (ru) ТЕТРАГИДРОИЗОХИНОЛИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ АКТИВАТОРОВ Nrf2
HK40088671B (en) Isoquiniline nrf2 agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant